Search
ASGCT 2026: Aurion Biotech is developing an off the shelf cell therapy solution for Corneal endothelial disease, a type of blindness, where only donor transplants are currently available to some
Founder, CSO & CEO Arnaud Lacoste describes the treatment, which is derived from one donor and can treat up to 1,000 patients, and comes in a solution containing a rho-kinase inhibitor. It is currently in a U.S. pivotal study. Coverage brought to you by
May 15
.png){kind=logo}